Polyrizon Ltd. (Nasdaq: PLRZ), a biotechnology company specializing in the development of intranasal products, has announced that it has successfully regained compliance with Nasdaq listing requirements. The company received formal confirmation from the Nasdaq Hearings Panel that it meets the minimum bid price requirement, as outlined in Nasdaq Listing Rule 5550(a)(2). This follows a previous decision by the Nasdaq Hearings Panel on July 9, 2025, and allows Polyrizon to continue trading on the Nasdaq Capital Market under its existing ticker symbol.
Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Polyrizon Ltd. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: GNW9512619-en) on August 14, 2025, and is solely responsible for the information contained therein.